Pieris Pharmaceuticals, Inc. - Special Call Transcript
(technical difficulty) the nonactive dose and the active dose ranges. As Ingmar pointed out in the introduction, the impact of our drug on CD8 T cells was something that we were particularly interested in. And for that reason, we explored CD8 T cell density in the tumor microenvironment. What we observed was that we got increased -- we saw an increased T cell signature above cohort 9, that's statistically significant and marked here in green, yellow and red are those patients that were receiving or obtaining complete response, partial response to our long-lasting, stable disease, and all having significant increases in CD8 T cell level.
And also another exploratory biomarker that we're interested in looking at was soluble 4-1BB. So as 4-1BB's pathway is activated, the T cells secrete soluble 4-1BB in a kind of a negative feedback loop. What we observed here is that, again, in our nonactive cohorts, we don't see any real modulation. But as soon as we go to that active dose range, we see nice modulation of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |